Bicycle Therapeutics Ltd (BCYC)
NASDAQ:BCYC
Top Page
Bicycle Therapeutics
(NASDAQ:BCYC)
Select Model
Select Model
Rating:46Neutral
Price Target:
$5.00
▲(0.40% Upside)
Action:ReiteratedDate:03/19/26
The score is primarily held back by weak financial quality—large ongoing losses and an accelerating cash burn—despite strong revenue growth and a relatively low-debt balance sheet. Technicals also reflect a sustained downtrend and weak momentum. A positive corporate update and stated runway into 2028 provide some support, but do not fully offset the funding and profitability risks implied by current cash outflows.
Positive Factors
Revenue Growth
Sustained, multi-year revenue acceleration demonstrates commercial and partner validation of the Bicycle platform. Higher recurring collaboration and milestone revenue can fund R&D, strengthen bargaining power with partners, and support longer-term pipeline advancement even before product approval.
Negative Factors
Large Ongoing Losses
Substantial recurring net losses erode shareholder equity and reflect high fixed R&D and development costs inherent to clinical-stage biotech. Persisting losses constrain self-funding ability, increase reliance on external capital, and can limit strategic optionality if clinical outcomes slow.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Sustained, multi-year revenue acceleration demonstrates commercial and partner validation of the Bicycle platform. Higher recurring collaboration and milestone revenue can fund R&D, strengthen bargaining power with partners, and support longer-term pipeline advancement even before product approval.
Read all positive factors
Bicycle Therapeutics (BCYC) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$342.68M
Dividend YieldN/A
Average Volume (3M)496.53K
Price to Earnings (P/E)―
Beta (1Y)1.63
Revenue Growth-23.43%
EPS Growth-9.84%
CountryUS
Employees305
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.29
Shares Outstanding50,269,080
10 Day Avg. Volume343,762
30 Day Avg. Volume496,532
Financial Highlights & Ratios
PEG Ratio-0.26
Price to Book (P/B)0.80
Price to Sales (P/S)6.76
P/FCF Ratio-1.94
Enterprise Value/Market Cap-0.78
Enterprise Value/Revenue-3.66
Enterprise Value/Gross Profit2.93
Enterprise Value/Ebitda1.13
Forecast
1Y Price Target
$14.33Price Target Upside187.75% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)-2.18
Revenue Forecast (FY)$31.35M
Bicycle Therapeutics Business Overview & Revenue Model
Company Description
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phas...
How the Company Makes Money
Bicycle Therapeutics primarily makes money through (1) collaboration and licensing arrangements and (2) other early-stage, non-product revenue sources typical of a clinical-stage biotech, rather than from selling approved medicines. Under collabor...
Bicycle Therapeutics Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
72
Positive
Cash Flow
24
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 72.59M | 35.27M | 26.98M | 14.46M | 11.70M |
| Gross Profit | 72.59M | -137.69M | -129.52M | 14.46M | 11.70M |
| EBITDA | -276.86M | -164.89M | -183.40M | -107.21M | -64.09M |
| Net Income | -218.96M | -169.03M | -180.66M | -112.72M | -66.82M |
Balance Sheet | |||||
| Total Assets | 717.60M | 956.87M | 595.34M | 410.61M | 479.79M |
| Cash, Cash Equivalents and Short-Term Investments | 628.11M | 879.52M | 526.42M | 339.15M | 438.68M |
| Total Debt | 17.52M | 9.49M | 44.96M | 44.33M | 44.34M |
| Total Liabilities | 107.62M | 163.81M | 224.41M | 139.83M | 133.54M |
| Stockholders Equity | 609.98M | 793.06M | 370.93M | 270.78M | 346.25M |
Cash Flow | |||||
| Free Cash Flow | -252.61M | -165.96M | -63.56M | -105.10M | -16.82M |
| Operating Cash Flow | -249.68M | -164.72M | -60.63M | -86.11M | -14.79M |
| Investing Cash Flow | -2.35M | -1.24M | -2.93M | -18.99M | -2.03M |
| Financing Cash Flow | -131.00K | 519.75M | 250.03M | 6.69M | 320.73M |
Bicycle Therapeutics Technical Analysis
Neutral
4.98
Price Trends
5.24
Negative
6.06
Negative
6.83
Negative
Market Momentum
-0.10
Negative
49.53
Neutral
80.39
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BCYC, the sentiment is Neutral. The current price of 4.98 is above the 20-day moving average (MA) of 4.72, below the 50-day MA of 5.24, and below the 200-day MA of 6.83, indicating a neutral trend. The MACD of -0.10 indicates Negative momentum. The RSI at 49.53 is Neutral, neither overbought nor oversold. The STOCH value of 80.39 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for BCYC.
Bicycle Therapeutics Risk Analysis
Bicycle Therapeutics disclosed 75 risk factors in its most recent earnings report. Bicycle Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Bicycle Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | $719.22M | 76.71 | -18.84% | ― | 102.77% | -17.00% | |
65 Neutral | $2.67B | -6.47 | -246.19% | ― | ― | -12.93% | |
62 Neutral | $1.38B | -6.67 | -32.49% | ― | ― | -103.95% | |
54 Neutral | $1.46B | -39.27 | 31.23% | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $342.68M | -2.24 | -33.20% | ― | -23.43% | -9.84% |
* Healthcare Sector Average
BCYC
Bicycle Therapeutics
4.98
-2.81
-36.07%
KOD
Kodiak Sciences
41.95
39.64
1716.02%
ETON
Eton Pharmaceuticals
26.05
11.86
83.58%
NBTX
Nanobiotix
32.00
28.59
838.42%
BCAX
Bicara Therapeutics Inc.
22.14
10.69
93.36%
Bicycle Therapeutics Corporate Events
Business Operations and Strategy
Bicycle Therapeutics Sets 2026 Oncology and Radiopharma Priorities
Positive
Jan 12, 2026
On January 12, 2026, Bicycle Therapeutics outlined its 2025 achievements and strategic priorities for 2026, emphasizing clinical progress in its oncology pipeline and expansion of its radiopharmaceutical capabilities. During 2025 the company advan...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.